Endometrial cancer (EC) ranks as the second most prevalent gynecologic malignancy globally, with approximately 189,000 new ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.

Obesity is a growing concern worldwide, including in low- and middle-income countries (LMICs). Addressing this issue involves various strategies, including dietary and lifestyle changes, medical ...

A new study published in Physiology & Behavior uncovers significant sensory implications of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), medications commonly prescribed for weight loss and ...

The Wagoner County Sheriff's Office (WCSO) released body cam video of deputies responding to a diabetic driver who went off the roadway and crashed into a tree ...

Objective—Glucagon-like peptide 1 (GLP-1 ... Previous studies have focused on the improvements in β-cell function, while the inhibition of α-cell secretion has received less attention.

While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

H.C. Wainwright reaffirmed a positive stance on Altimmune (NASDAQ:ALT) shares, maintaining a Buy rating and a $12.00 price target. Currently trading at $6.99 with a market capitalization of $497 ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...

Neurons in the brains of mice tell them to stop eating when they’ve had enough food – and since people probably have the same ...